Jodie Crawford

Mrs. Jodie Crawford


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Respiratory Medicine
Verified
Journal Article
Open access
NBNawar Diar Bakerly
Nawar Diar Bakerly
AWAshley Woodcock
Ashley Woodcock
SCSusan Collier
Susan Collier
DLDavid A. Leather
David A. Leather
JNJohn P. New
John P. New
IBIsabelle Boucot
Isabelle Boucot
SLS COPD was the first open-label randomised controlled trial demonstrating a reduction in moderate/severe COPD exacerbations with once-daily inhaled fluticasone furoate/vilanterol (FF/VI) in everyday clinical practice. Here we report FF/VI effectiveness and safety in predefined patient subgroups. Patients with COPD, exacerbation history, and receiving maintenance inhaler therapy, were randomised to initiate FF/VI 100/25 μg or continue usual care (UC) with 12 months' follow-up. Annual rates of moderate/severe exacerbations (primary outcome), selected secondary outcomes, and incidence of pneumonia serious adverse events of special interest (SAESI) were compared between randomisation groups across various patient subgroups/baseline treatment strata. SAESI rates by actual treatment were also assessed. Lower exacerbation rates were observed for FF/VI versus UC across all subgroups/strata, including ICS + LABA therapy subset (8.0% [0.1, 15.4]), except in patients without baseline airflow limitation (-0.5% [-29.8, 22.1]). Larger reductions compared to the overall analysis were observed for patients on ICS-containing regimens (excluding LAMA) before the study (15.6% [3.4, 26.3]), and with baseline CAT score <10 (25.3% [-0.4, 44.4]). Pneumonia SAESI rates were similar for FF/VI versus UC across all subgroups/strata, except the LABA, LAMA or LABA + LAMA stratum (incidence ratio 2.8 [0.9, 8.5]). SAESI rates were not increased for FF/VI versus other ICS + LABA. Initiating FF/VI versus continuing UC reduced exacerbation rates without increased pneumonia SAESI risk compared to other ICS-containing regimens and in various patient subgroups, consistent with primary study findings. FF/VI may be a therapeutic option for a broad population of COPD patients, including those with more severe disease.

14 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SHSoichiro Hozawa
Soichiro Hozawa
RIRisako Ito
Risako Ito
JCJodie Crawford
Jodie Crawford
RHRyota Hibi
Ryota Hibi
AMAlison Moore
Alison Moore
SNStephen G. Noorduyn
Stephen G. Noorduyn
Background/Objectives: Clinical remission (CR) is an ambitious and attainable treatment goal for asthma; however, CR definitions vary. Evidence of CR in Japanese patients with moderate-to-severe asthma on inhaled therapies is lacking and was evaluated based on three guideline definitions: the United States Workgroup consensus statement, Japanese Guidelines for adult asthma (JGL), and Practical Guidelines for Asthma Management (PGAM). Methods: Post hoc analysis of Phase III studies including Japanese participants: Japanese subpopulation of CAPTAIN (NCT02924688) and a 52-week Japanese long-term safety study (NCT03184987). CAPTAIN randomized participants to once-daily fluticasone furoate/vilanterol (FF/VI) regimens ± umeclidinium (UMEC). The long-term safety study allocated participants to once-daily FF/UMEC/VI based on asthma control status. All three CR definitions assessed systemic corticosteroid use, severe exacerbations, and asthma control (Asthma Control Questionnaire-5 <1.5 [Workgroup] or ≤0.75 [JGL/PGAM]); Workgroup and JGL also assessed lung function (change from baseline in trough forced expiratory volume in 1 s of ≥0 [stabilized] or ≥100 mL [optimized]). Results: CR attainability varied on definition and thresholds used. At Week 24 in the CAPTAIN Japanese subpopulation, 34–59% and 18–45% of participants (Workgroup; stabilized and optimized), and 21–34% and 8–24% (JGL; stabilized and optimized) met CR criteria across treatment arms. At Week 52 in the long-term safety study, equivalent figures for CR achievement were 33–60%, 22–45%, 11–28%, and 11–23%. Conclusions: This analysis demonstrates that CR, using different definitions and criteria, is an attainable treatment goal with inhaled therapy in Japanese patients with moderate-to-severe asthma not yet eligible for biologics.

5 September 2026
Verified
Conference Paper
Closed access
JCJodie Crawford
Jodie Crawford
EPErika Penz
Erika Penz
SNStephen G Noorduyn
Stephen G Noorduyn
AMAlison C Moore
Alison C Moore
HNHiroyuki Nagase
Hiroyuki Nagase
JOJohn J Oppenheimer
John J Oppenheimer
Rationale Asthma is associated with reduced quality of life (QoL), which greatly impacts patients. Traditional randomised controlled trials (RCTs) have shown lung function and symptom improvements with ICS/LAMA/LABA versus ICS/LABA in moderate/severe asthma; however, evidence for QoL with triple versus dual therapy in routine practice is limited. Methods PERFORM is a 52-week, global, pragmatic, open-label RCT evaluating the effectiveness and safety of initiating FF/UMEC/VI ELLIPTA versus initiating or continuing non-ELLIPTA ICS/LABA usual care in adults with uncontrolled asthma. Secondary endpoints included change from baseline in AQLQ12+ and WPAI:Asthma scores at Week 24, assessed using ANCOVA; analyses were unadjusted for multiplicity. Results Patients (FF/UMEC/VI N=619; ICS/LABA N=617) had a mean ACQ-7 score of 2.46 and FEV1 %predicted of 85.74 at baseline. At Week 24, FF/UMEC/VI led to greater improvements in AQLQ12+ total score and symptom and activity domain scores, and WPAI:Asthma activity impairment score, versus ICS/LABA (Table). The safety profile to Week 24 aligned with prior studies. Conclusions Compared with non-ELLIPTA ICS/LABA, FF/UMEC/VI improved asthma-related QoL in a broad population with uncontrolled asthma representative of real-world patients treated in routine practice. Initiating FF/UMEC/VI improved patients’ daily living, raising treatment expectations for early intervention in patients with symptomatic asthma and uncompromised lung function. Funding GSK (219912; NCT06372496) erj;68/suppl_70/PA357/F1 F1 F1